Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH
Results support potential of efruxifermin ( EFX ) to reduce risk of fibrosis progression in patients with pre-cirrhotic ( F2-F3 ) MASH Results support potential of efruxifermin ( EFX ) to reduce risk of fibrosis progression in patients with pre-cirrhotic ( F2-F3 ) MASH ...
Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus
ALLO posts a narrower second-quarter 2025 loss. The company advances multiple CAR T programs targeting cancer and autoimmune diseases.
Are Medical Stocks Lagging Akero Therapeutics ( AKRO ) This Year?
Here is how Akero Therapeutics, Inc. (AKRO) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
Akero ( AKRO ) Q2 Loss Narrows 6%
Akero Therapeutics ( NASDAQ:AKRO ) , a biotechnology company focused on developing medicines for fatty liver diseases, released its second-quarter results on August 8, 2025. The most notable news in this quarter was continued progress in clinical trials for its lead drug candidate, efruxifermin ( ...
Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of Medicine ...
This AeroVironment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Akero Therapeutics ( NASDAQ:AKRO ) , Apartment Inv & Mgmt ( NYSE:AIV )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. TD Cowen analyst Ritu Baral initiated coverage on Akero Therapeutics, Inc.
Altimmune Gears Up to Report Q2 Earnings: Here's What to Expect
ALT readies Q2 report as investors await fresh updates on pemvidutide program in obesity and liver disease studies.
Amarin Gears Up to Report Q2 Earnings: Here's What to Expect
AMRN braces up for second-quarter results as U.S. Vascepa sales are likely to slide, while growth in the EU looks imminent.
Incyte Gears Up to Report Q2 Earnings: Is a Beat in the Cards?
INCY eyes strong Q2 performance with Jakafi, Opzelura, and new launches like Niktimvo driving revenues.
VKTX Stock Down on Wider-Than-Expected Loss in Q2, Nil Sales
Shares of Viking slide after Q2 loss widens to 58 cents per share on rising R&D and nil revenues, missing estimates by 14 cents.
Exelixis' Q2 Earnings: Will Cabometyx Sales Drive Growth?
EXEL investors eye Cabometyx sales and zanzalintinib trial results ahead of Q2 earnings release on July 28.
Viking Therapeutics Gears Up for Q2 Earnings: Here's What to Expect
With no revenue expected, VKTX's Q2 report is likely to have the spotlight on pipeline moves across its obesity drugs.
RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure
Rocket Pharmaceuticals jumps 16.8% as FDA grants RMAT status to RP-A601 on positive phase I heart disease data.
FDA Advisory Panel Votes Against Approval of GSK's Blenrep Combo
GSK stock falls as an FDA panel votes against its Blenrep combo, casting doubt on U.S. approval hopes.
AstraZeneca's AL Amyloidosis Drug Misses Goal in Late-Stage Studies
AZN's anselamimab fails to meet key goals in late-stage AL amyloidosis trials despite signs of subgroup benefit.
Mirum Gains 35% in 3 Months: How Should You Play the Stock?
MIRM jumps 35% in 3 months, driven by soaring Livmarli sales and rising demand for its bile acid products.
Sanofi's Gene Therapy for Eye Disease Gets FDA's Fast Track Tag
SNY's SAR446597, a one-time intravitreal gene therapy, secures FDA fast track tag for geographic atrophy due to age-related macular degeneration.
Corcept Seeks FDA Approval for Relacorilant in Ovarian Cancer
CORT's relacorilant combo targets platinum-resistant ovarian cancer in new NDA, backed by positive ROSELLA study data.
Akero Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - Akero Therapeutics ( NASDAQ:AKRO )
SOUTH SAN FRANCISCO, Calif., June 03, 2025 ( GLOBE NEWSWIRE ) -- Akero Therapeutics, Inc.
Akero Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., June 03, 2025 ( GLOBE NEWSWIRE ) -- Akero Therapeutics, Inc. ( Nasdaq: AKRO ) , a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will ...
Akero Therapeutics to Present at the Jefferies Global Healthcare Conference - Akero Therapeutics ( NASDAQ:AKRO )
SOUTH SAN FRANCISCO, Calif., May 28, 2025 ( GLOBE NEWSWIRE ) -- Akero Therapeutics, Inc. AKRO, a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the ...
Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025
Analysis of EFX results with AI-based digital pathology underscores the potential value in evaluating histopathology response ...
Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025
SOUTH SAN FRANCISCO, Calif., May 09, 2025 ( GLOBE NEWSWIRE ) -- Akero Therapeutics, Inc. ( Nasdaq: AKRO ) , a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, presented results from the Phase 2b SYMMETRY ...
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine
Results support potential benefit of efruxifermin ( EFX ) to elicit fibrosis improvement in patients with compensated cirrhosis ( F4 fibrosis ) due to MASH 96-week data from SYMMETRY trial presented at EASL Congress ...
Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025
SOUTH SAN FRANCISCO, Calif., May 09, 2025 ( GLOBE NEWSWIRE ) -- Akero Therapeutics, Inc. ( Nasdaq: AKRO ) , a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, presented results from the Phase 2b SYMMETRY ...
Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025 - Akero Therapeutics ( NASDAQ:AKRO )
SOUTH SAN FRANCISCO, Calif., May 09, 2025 ( GLOBE NEWSWIRE ) -- Akero Therapeutics, Inc.
ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders - Keros Therapeutics ( NASDAQ:KROS )
Announces Intention to Withhold Votes for Directors Dr. Mary Ann Gray and Dr. Alpna Seth
Long-Term Shareholders Have Rights - If You Hold Akero Therapeutics, Inc. ( NASDAQ: AKRO ) ; Integra Lifesciences Holdings Corporation ( NASDAQ: IART ) ; Mercury Systems, Inc. ( NASDAQ: MRCY ) ; or Virtu Financial Inc. ( NASDAQ: VIRT ) , Contact Grabar Law Office - Integra Lifesciences ( NASDAQ:IART ) , Akero Therapeutics ( NASDAQ:AKRO )
PHILADELPHIA, May 05, 2025 ( GLOBE NEWSWIRE ) -- Akero Therapeutics, Inc. AKRO: Grabar Law Office is investigating whether certain officers and directors of Akero breached their fiduciary duties owed to the company. If you have held Akero Therapeutics, Inc.
Akero Therapeutics Announces Upcoming Poster and Oral Presentations at the EASL Congress 2025 - Akero Therapeutics ( NASDAQ:AKRO )
SOUTH SAN FRANCISCO, Calif., April 30, 2025 ( GLOBE NEWSWIRE ) -- Akero Therapeutics, Inc.
INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law Firm - Akero Therapeutics ( NASDAQ:AKRO )
NEW YORK, April 23, 2025 ( GLOBE NEWSWIRE ) -- Moore Law, PLLC, a shareholder litigation law firm located on Wall Street, is investigating potential claims against: Shareholders should email [email protected]; please contact only if shares acquired before September 13, 2022
INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law Firm - Akero Therapeutics ( NASDAQ:AKRO )
NEW YORK, April 07, 2025 ( GLOBE NEWSWIRE ) -- Moore Law, PLLC, a shareholder litigation law firm located on Wall Street, is investigating potential claims against: Shareholders should email [email protected]; please contact only if shares acquired before September 13, 2022
Notice to Long-Term Shareholders of Akero Therapeutics, Inc. ( Nasdaq: AKRO ) ; Driven Brands Holdings, Inc. ( Nasdaq: DRVN ) ; Integra Lifesciences Holdings Corporation ( Nasdaq: IART ) ; and Kyverna Therapeutics, Inc. ( Nasdaq: KYTX ) : Grabar Law Office is Investigating Claims on Your Behalf - Driven Brands Hldgs ( NASDAQ:DRVN ) , Akero Therapeutics ( NASDAQ:AKRO )
PHILADELPHIA, March 24, 2025 ( GLOBE NEWSWIRE ) -- Akero Therapeutics, Inc. AKRO: Grabar Law Office is investigating whether certain officers and directors of Akero breached their fiduciary duties owed to the company. If you have held Akero Therapeutics, Inc.
Is Agilon Health ( AGL ) Outperforming Other Medical Stocks This Year?
Here is how Agilon Health (AGL) and Akero Therapeutics, Inc. (AKRO) have performed compared to their sector so far this year.
Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
-- Reported unprecedented, statistically significant reversal of compensated cirrhosis ( F4 ) due to MASH after 96 weeks of treatment with efruxifermin ( EFX ) in Phase 2b SYMMETRY study -- -- Completed enrollment of the double-blinded portion of the Phase 3 SYNCHRONY Real-World Study evaluating ...
Grabar Law Office is Investigating Claims on Behalf of Long-Term Shareholders of Akero Therapeutics, Inc. ( NASDAQ: AKRO ) ; Crocs, Inc. ( NASDAQ: CROX ) ; Extreme Networks, Inc. ( NASDAQ: EXTR ) ; and Domino's Pizza Corp. ( NASDAQ: DPZ ) - Crocs ( NASDAQ:CROX ) , Akero Therapeutics ( NASDAQ:AKRO )
PHILADELPHIA, Feb. 20, 2025 ( GLOBE NEWSWIRE ) -- Grabar Law Office is investigating whether certain officers and directors of Akero breached their fiduciary duties owed to the company. If you have held Akero Therapeutics, Inc.
This Stock Just Doubled in 1 Day -- Is It Still a Buy?
We are still pretty early in the new year, but some companies are already delivering outsize returns to their shareholders. Akero Therapeutics ( NASDAQ: AKRO ) is part of this group. On Jan. 27, the company's shares soared by 97%, closing the day at $51.71.
Akero Therapeutics, Brinker International And Viavi Are Among Top Mid Cap Gainers Last Week ( Jan 27-Jan 31 ) : Are The Others In Your Portfolio? - Akero Therapeutics ( NASDAQ:AKRO ) , Brinker International ( NYSE:EAT )
Akero Therapeutics shares soared 106.57% after promising results from its Phase 2B SYMMETRY study of Efruxifermin. Surgery Partners increased 25.44% following a non-binding acquisition offer from Bain Capital. Get Wall Street's Hottest Chart Every Morning
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics
Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics are part of the Zacks top Analyst Blog.
Biotech Stock Roundup: SAGE Up on Declining BIIB's Offer, CYTK, AKRO Up on Updates
SAGE and AKRO are up this week on regulatory and pipeline updates.
AKRO Stock Doubles in a Week as Lead Drug Meets Goal in MASH Study
Akero stock soars 106% in a week following initial positive top line 96-week data from a mid-stage MASH study of its lead product candidate, EFX.
Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
SOUTH SAN FRANCISCO, Calif., Jan. 28, 2025 ( GLOBE NEWSWIRE ) -- Akero Therapeutics, Inc. ( Nasdaq: AKRO ) , a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today the pricing of an upsized ...
Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants - Akero Therapeutics ( NASDAQ:AKRO )
SOUTH SAN FRANCISCO, Calif., Jan. 28, 2025 ( GLOBE NEWSWIRE ) -- Akero Therapeutics, Inc.
Royal Caribbean Cruises Posts Upbeat Earnings, Joins Brighthouse Financial, Invesco, Boeing And Other Big Stocks Moving Higher On Tuesday - Atlas Energy Solutions ( NYSE:AESI ) , Akero Therapeutics ( NASDAQ:AKRO )
U.S. stocks were mixed, with the Dow Jones index falling around 0.1% on Tuesday. Shares of Royal Caribbean Cruises Ltd. RCL gained 6.2% to $251.48 following a fourth-quarter EPS beat. Adjusted EBITDA for the quarter was $1.09 billion, with a margin of 29.2%.
McDonald's To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday - Autodesk ( NASDAQ:ADSK ) , Akero Therapeutics ( NASDAQ:AKRO )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Barclays raised the price target for Victoria's Secret & Co. VSCO from $51 to $53.
S&P 500 Falls Over 100 Points; Dada Nexus Shares Spike Higher - Allakos ( NASDAQ:ALLK ) , Akero Therapeutics ( NASDAQ:AKRO )
U.S. stocks traded mixed toward the end of trading, with the S&P 500 falling over 100 points on Monday. The Dow traded up 0.22% to 44,521.81 while the NASDAQ fell 3.29% to 19,297.13. The S&P 500 also fell, dropping, 1.84% to 5,988.74. Health care shares surged by 2% on Monday.
Dow Edges Higher; AT&T Posts Upbeat Earnings - Allakos ( NASDAQ:ALLK ) , Akero Therapeutics ( NASDAQ:AKRO )
U.S. stocks traded mostly lower midway through trading, with the Dow Jones index edging higher on Monday. The Dow traded up 0.04% to 44,440.59 while the NASDAQ fell 2.96% to 19,364.21. The S&P 500 also fell, dropping, 1.72% to 5,996.25. Consumer staples shares surged by 1.1% on Monday.
Dogecoin And Shiba Inu Drop 10% As Bitcoin Falls Below $100,000; Trump Drops 50% Tariff Threat On Colombian Imports After Deportation Agreement; AT&T Q4 Earnings Beat Expectations, Forecasts Mid-Teens Broadband Growth By 2025 - Top Headlines While The U.S. Slept
MicroStrategy's Bitcoin Buying Spree Continues, Accumulates Over 10,000 BTC Bitcoin Flash-Crashes To $98,000 On China AI Fears, Trump Disappointment Dogecoin, Shiba Inu Plummet 10% As Bitcoin Slips Below $100,000
Dada Nexus, Titan Machinery, AT&T And Other Big Stocks Moving Higher On Monday - Dada Nexus ( NASDAQ:DADA ) , Akero Therapeutics ( NASDAQ:AKRO )
U.S. stocks were lower, with the Dow Jones index falling over 100 points on Monday. Shares of Dada Nexus Limited DADA rose sharply during Monday's session after the company received a preliminary, non-binding proposal from JD.com, Inc.
Nasdaq Dips 3%; Chicago Fed National Activity Index Rises In December - Allakos ( NASDAQ:ALLK ) , Akero Therapeutics ( NASDAQ:AKRO )
U.S. stocks traded lower this morning, with the Nasdaq Composite falling over 600 points on Monday. Following the market opening Monday, the Dow traded down 0.33% to 44,276.05 while the NASDAQ fell 3.08% to 19,340.76. The S&P 500 also fell, dropping, 1.74% to 5,994.91.
Why Is Akero Therapeutics Stock Soaring Over 100% On Monday? - Akero Therapeutics ( NASDAQ:AKRO )
Akero's 50mg EFX led to a 24% effect size for cirrhosis reversal over placebo in week 96 biopsies, highlighting treatment potential. Non-GLP-1 subgroup saw 45% cirrhosis reversal with EFX, showing benefits are independent of GLP-1 therapy. Get Wall Street's Hottest Chart Every Morning
